|
|
|
|
|
|
Sponsored by: |
Novartis |
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00416845 |
This study is designed to assess the effects of two doses of FTY720 on lung (pulmonary) and cardiac (heart) functions in healthy volunteers.
Condition | Intervention | Phase |
Healthy |
Drug: FTY720 |
Phase I |
Drug Information available for: | FTY 720 Fingolimod S 1 (Combination) |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Pharmacokinetics/Dynamics Study |
Official Title: | A Randomized, Parallel Group, Double-Blind, Placebo Controlled, 14 Days Multiple-Dose Treatment to Assess the Pulmonary and Cardiac Pharmacodynamics of FTY720 (0.5 and 1.25 mg) in Healthy Volunteers |
Estimated Enrollment: | 36 |
Study Start Date: | October 2006 |
Ages Eligible for Study: | 19 Years to 50 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Study ID Numbers: | CFTY720D2105 |
First Received: | December 27, 2006 |
Last Updated: | June 18, 2007 |
ClinicalTrials.gov Identifier: | NCT00416845 |
Health Authority: | United States: Food and Drug Administration |
|
|
|